azacitidine and hydrazine

azacitidine has been researched along with hydrazine in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (17.65)29.6817
2010's9 (52.94)24.3611
2020's5 (29.41)2.80

Authors

AuthorsStudies
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Craig, CM; Schiller, GJ1
Gore, SD1
Sekeres, MA1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A1
Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T1
Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X1
Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J1
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N1
Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C1
Estey, EH; Percival, MM1
Criscuolo, M; Cupelli, E; D'Alò, F; De Stefano, V; Fabiani, E; Falconi, G; Fianchi, L; Hohaus, S; Pagano, L; Zangrilli, I1
Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L1
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J1
Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H1
Boucher, R; Bowen, D; Cargo, C; Coulthard, HC; Culligan, D; Dennis, M; Jackson, A; Metzner, M; Moore, R; O'Sullivan, J; Raghavan, M; Sternberg, A; Vyas, P1

Reviews

5 review(s) available for azacitidine and hydrazine

ArticleYear
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
    Blood reviews, 2008, Volume: 22, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides

2008
Treatment of MDS: something old, something new, something borrowed...
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin

2009
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
    Current medicinal chemistry, 2011, Volume: 18, Issue:5

    Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1

2011
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    The Cochrane database of systematic reviews, 2017, 09-30, Volume: 9

    Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin

2017
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019

Trials

4 trial(s) available for azacitidine and hydrazine

ArticleYear
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    European journal of haematology, 2014, Volume: 93, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis

2014
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:8

    Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome

2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    The Lancet. Haematology, 2020, Volume: 7, Issue:8

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles

2020
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
    British journal of haematology, 2022, Volume: 199, Issue:2

    Topics: Azacitidine; Benzoates; Drug Combinations; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome

2022

Other Studies

8 other study(ies) available for azacitidine and hydrazine

ArticleYear
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
New agents for the treatment of AML recent study findings.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide

2008
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation

2015
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    International journal of hematology, 2017, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin

2017
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Medicine, 2017, Volume: 96, Issue:43

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome

2017
    Platelets, 2021, Apr-03, Volume: 32, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Humans; Hydrazines; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thrombopoiesis

2021
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
    Investigational new drugs, 2022, Volume: 40, Issue:4

    Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53

2022